Immune Zoomer: A Clinical Case Report

This case simulation—grounded in patterns observed across hundreds of clinical consultations—is designed to support evidence-informed interpretation of the Immune Zoomer Sample Report.

Clinical Narrative

A 52-year-old male presents with a 3-month history of progressive bilateral hand and foot pain, swelling, and morning stiffness lasting approximately 90 minutes each morning.

Symptoms began in the metacarpophalangeal joints of both hands and have since progressed to involve the proximal interphalangeal joints and metatarsophalangeal joints bilaterally. He reports difficulty gripping tools and opening jars, which is especially relevant given his work in construction.

He also reports fatigue and an unintentional 4-pound weight loss over the past 2 months. 

Relevant history includes:

• Hypertension
• Hyperlipidemia
• Family history of rheumatoid arthritis (RA) (mother)
• Occupational history involving repetitive manual labor and potential environmental exposures through construction work

He denies recent infections, rashes, ocular symptoms, back pain, dysuria, oral ulcers, and gastrointestinal symptoms.

Current medications include lisinopril and atorvastatin. Ibuprofen 400 mg as needed for joint pain provides partial relief.

Key Clinical Findings

1. Inflammatory Polyarthritis with Rheumatoid Arthritis-Associated Immune Reactivity

The patient’s clinical presentation is notable for symmetric inflammatory polyarthritis involving the small joints of the hands and feet, prolonged morning stiffness, fatigue, and functional impairment.

Immune Zoomer findings include:

• Rheumatoid Factor (RF): 25.0 IU/mL — elevated
  
• Citrullinated Peptide Antibodies (CCP3): 21.1 — moderately elevated
• Collagen type II: 3.45 — highly elevated
  

Together, these findings support an immune reactivity pattern associated with seropositive rheumatoid arthritis when interpreted in the context of the patient’s symptoms, family history, and clinical presentation.

This pattern is clinically meaningful because RA is not diagnosed by a single laboratory marker. Rather, RA is a clinical diagnosis that requires correlation with history, physical exam findings, inflammatory markers, autoantibody results, and, when appropriate, imaging or additional laboratory evaluation.

• Citrullinated Peptide (CCP3) antibodies are considered highly specific for RA, particularly in established disease. However, anti-CCP may be present in only a subset of patients with early RA, which makes clinical correlation especially important in early inflammatory presentations.

• Rheumatoid Factor (RF) immune reactivity is diagnostically useful but is not specific to RA. RF may also be seen in other autoimmune, inflammatory, or infectious conditions, including hepatitis C, systemic lupus erythematosus, dermatomyositis, polymyositis, sarcoidosis, and mixed connective tissue disease.

• Collagen type II immune reactivity may be relevant in inflammatory joint disease, but it is not specific to RA and may be seen in other inflammatory or autoimmune conditions, including ankylosing spondylitis, autoimmune connective tissue diseases, and chronic inflammatory syndromes.

In this case, the patient’s joint distribution, duration of symptoms, prolonged morning stiffness, family history, and RA-associated serologies are consistent with a seropositive RA pattern and warrant rheumatology evaluation.

2. Elevated hsCRP Reflecting Systemic Inflammation

The patient’s hsCRP is elevated at 7.4.

This supports the presence of systemic inflammation and aligns with the patient’s active inflammatory joint symptoms. Elevated hsCRP may be seen in active autoimmune and inflammatory conditions and may help clinicians monitor inflammatory burden over time.

However, hsCRP is not specific to RA or any single autoimmune condition. It should be interpreted alongside the patient’s clinical presentation, autoantibody profile, and other relevant findings.

3. ANA Positive With Homogeneous Pattern

The patient is ANA positive with a homogeneous pattern and a titer of 1:320.

ANA titers reflect the concentration of antibodies, reported as serial dilutions. Higher titers, such as 1:160 or above, may increase the pretest probability of systemic autoimmune disease, while lower titers may be seen in healthy individuals.

A homogeneous ANA pattern may be associated with systemic lupus erythematosus (SLE). However, this patient does not report characteristic clinical features of SLE, such as malar rash, oral ulcers, serositis, renal disease, leukopenia, or anemia. Furthermore, anti-dsDNA and anti-Smith antibodies are not elevated.

In this context, ANA positivity may reflect immune activation occurring alongside the RA-associated pattern rather than indicating a separate SLE presentation. ANA findings should be interpreted with clinical correlation and, when appropriate, additional evaluation.

4. Moderately Elevated Anti-tTG IgA

The patient’s anti-tissue transglutaminase IgA is moderately elevated at 0.99.

This finding may warrant further assessment for celiac disease or related gluten-associated immune activity, particularly if symptoms evolve. At the time of this case, the patient has no known family history of celiac disease.

Because autoimmune conditions may cluster, monitoring for gastrointestinal symptoms, persistent joint pain, fatigue, or continued unintentional weight loss may be clinically appropriate. Follow-up testing may be considered if symptoms persist despite RA-directed care or if additional celiac-associated symptoms emerge.

Why This Case Matters

This case demonstrates the importance of interpreting immune findings as patterns rather than isolated results.

The Immune Zoomer results show a clinically relevant pattern involving:

• RA-associated immune reactivity
• Systemic inflammation
• ANA positivity
• Possible gut-associated autoimmune activity

The findings align with the patient’s inflammatory joint symptoms and family history of RA, while also identifying additional immune signals that may influence follow-up evaluation.

For providers, this case highlights how expanded immune profiling may help contextualize early immune dysregulation, especially when symptoms are evolving and multiple autoimmune pathways may be clinically relevant.

Clinical Considerations

Given this patient’s presentation and Immune Zoomer findings, clinicians may consider additional evaluation of:

• Rheumatoid arthritis and other inflammatory arthritides
• Disease activity and inflammatory burden
• ANA-associated systemic autoimmune conditions, if clinical features emerge
• Celiac disease or gluten-associated immune activity
• Cardiovascular risk in the context of inflammatory disease
• Occupational or environmental exposures that may contribute to immune burden
• Gut health factors associated with immune regulation

These considerations should be guided by the provider’s clinical assessment and may include additional laboratory evaluation, imaging, rheumatology referral, or specialty consultation as appropriate.

Potential Follow-Up Testing Considerations

Future Vibrant testing may be considered based on the patient’s history, symptoms, and provider judgment.

Wheat Antibodies

Wheat Antibodies testing may be considered to further assess immune reactivity associated with celiac disease, intestinal permeability, and non-celiac gluten sensitivity in the setting of moderately elevated anti-tTG IgA antibodies.

This may be especially relevant if the patient develops gastrointestinal symptoms or if joint pain, fatigue, or weight loss persist despite RA-directed treatment.

Cardio Zoomer

Cardio Zoomer may be considered to assess cardiovascular health in the context of RA-associated immune reactivity, hypertension, hyperlipidemia, and the increased cardiovascular risk observed in patients with RA.

Toxin Zoomer

Toxin Zoomer may be considered based on the patient’s occupational history as a construction worker, which may involve increased likelihood of exposure to inhaled or environmental toxicants. Multiple categories of environmental toxins have been shown to increase the risk and severity of RA, including pesticides, heavy metals, and volatile organic compounds. 

Environmental exposures should be interpreted in the context of the patient’s clinical history, exposure patterns, and provider assessment.

Gut Zoomer

Gut Zoomer may be considered to assess assess gut-joint immune crosstalk, gut dysbiosis, intestinal permeability, and gut inflammation, which have been associated with immune dysregulation and RA pathogenesis.

Summary

This case highlights how a patient presenting with early inflammatory joint symptoms may show a broader pattern of immune dysregulation on expanded immune testing.

Key findings include:

• Elevated rheumatoid factor
• Moderately elevated CCP3 antibodies
• Elevated collagen type II antibodies
• Elevated hsCRP
• Positive ANA with homogeneous pattern and 1:320 titer
• Moderately elevated anti-tTG IgA

Taken together, the patient’s symptoms and laboratory findings are consistent with a seropositive RA pattern, while the ANA and anti-tTG IgA findings provide additional context for broader immune evaluation.

The Immune Zoomer provides clinicians with a multi-system view of immune reactivity, helping identify patterns that may support earlier evaluation, more targeted follow-up, and more personalized clinical decision-making.